BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:The challenges in therapeutic targeting of the RAF-MEK-ERK signall
 ing pathway - Dr Simon Cook\, Babraham Institute
DTSTART:20200220T093000Z
DTEND:20200220T103000Z
UID:TALK135655@talks.cam.ac.uk
CONTACT:Louisa Bellis
DESCRIPTION:The ERK1/2 signalling pathway is de-regulated in a variety of 
 cancers due to mutations in RAS (especially KRAS)\, BRAF and MEK. This has
  led to the development of a variety of protein kinase inhibitors that tar
 get BRAF\, MEK or ERK. Indeed\, BRAF and MEK inhibitors are now approved f
 or treatment of melanomas harbouring BRAFV600E/K mutations.  This talk wil
 l highlight some of the challenges that these kinase inhibitors face - esp
 ecially intrinsic and acquired resistance - as well as some solutions.
LOCATION:Clinical School Lecture Theatre 2
END:VEVENT
END:VCALENDAR